Summer vibes means SensUs vibes. The SensUs Innovation Days 2019 will take place in about three months from now and the teams are working hard to show their best biosensors on the event. To keep you updated about the developments, here is our latest news!
As you may have noticed from this newsletter, SensUs is going through a rebranding process! The rebranding involves a complete overhaul of our house style and brand identity with an eye on the future. The new brand represents our mission to bring talents and stakeholders together, to become an international platform in biosensing, and to stimulate open innovation in point-of-care testing with a multidisciplinary approach.
Registration SensUs Innovation Days 2019
On the 30th of August the teams will present their results during the SensUs Innovation Days. Currently, they are working hard on their prototypes and business models, and are preparing for the journey to Eindhoven. The teams will present their works in an event full of students, industry, patients and healthcare professionals. The SensUs event is a unique chance to listen to inspiring talks, explore innovations and expand your network. Please register through the button below. Registration is free of charge.
In the SensUs competition, teams of students strive to make the best possible biosensors and win the SensUs awards. But how are the teams, and their prototypes, doing after the competition? We spoke with six alumni teams who told about their activities and recognition after the competition.
On the 20th of May, the SensUs Organization and team Glasgow 2018 gave a presentation at EuroMedLab, the large biannual European Congress of Clinical Laboratory Medicine, which this year took take place in Barcelona. This was a unique opportunity to inform academic and commercial experts in the field of Clinical Laboratory Medicine about the SensUs approach and achievements!
Personal Story Wendy
SensUs 2019 challenges 14 teams to develop biosensors for the detection of adalimumab, an important drug for patients with rheumatoid arthritis (RA). Patients suffering from RA experience constant pain and difficulty with everyday chores. Adalimumab relieves the symptoms by suppressing the body’s immune system. Adalimumab is a very expensive and the largest selling pharmaceutical drug worldwide. However, it is not an adequate treatment for every patient. Patients may not have benefits or may even lose treatment benefits over time.
RA is a disease that can strike already at a very young age. For SensUs Personal Stories, we talked to Wendy who got diagnosed with RA before her 18th birthday. This Personal Story was created together with Youth-R-Well, the organization for arthritis patients between the age of 16 and 30, and Perspektiv.